Merck
CN
  • Iron oxide nanoparticle-mediated development of cellular gap junction crosstalk to improve mesenchymal stem cells' therapeutic efficacy for myocardial infarction.

Iron oxide nanoparticle-mediated development of cellular gap junction crosstalk to improve mesenchymal stem cells' therapeutic efficacy for myocardial infarction.

ACS nano (2015-02-18)
Jin Han, Bokyoung Kim, Jung-Youn Shin, Seungmi Ryu, Myungkyung Noh, Jongsu Woo, Jin-Sil Park, Youjin Lee, Nohyun Lee, Taeghwan Hyeon, Donghoon Choi, Byung-Soo Kim
摘要

Electrophysiological phenotype development and paracrine action of mesenchymal stem cells (MSCs) are the critical factors that determine the therapeutic efficacy of MSCs for myocardial infarction (MI). In such respect, coculture of MSCs with cardiac cells has windowed a platform for cardiac priming of MSCs. Particularly, active gap junctional crosstalk of MSCs with cardiac cells in coculture has been known to play a major role in the MSC modification through coculture. Here, we report that iron oxide nanoparticles (IONPs) significantly augment the expression of connexin 43 (Cx43), a gap junction protein, of cardiomyoblasts (H9C2), which would be critical for gap junctional communication with MSCs in coculture for the generation of therapeutic potential-improved MSCs. MSCs cocultured with IONP-harboring H9C2 (cocultured MSCs: cMSCs) showed active cellular crosstalk with H9C2 and displayed significantly higher levels of electrophysiological cardiac biomarkers and a cardiac repair-favorable paracrine profile, both of which are responsible for MI repair. Accordingly, significantly improved animal survival and heart function were observed upon cMSC injection into rat MI models compared with the injection of unmodified MSCs. The present study highlights an application of IONPs in developing gap junctional crosstalk among the cells and generating cMSCs that exceeds the reparative potentials of conventional MSCs. On the basis of our finding, the potential application of IONPs can be extended in cell biology and stem cell-based therapies.

材料
货号
品牌
产品描述

Sigma-Aldrich
油酸, ≥99% (GC)
Sigma-Aldrich
油酸, technical grade, 90%
Sigma-Aldrich
罗丹明B, ≥95% (HPLC)
Sigma-Aldrich
油酸, suitable for cell culture, BioReagent
Sigma-Aldrich
罗丹明B, for fluorescence
Sigma-Aldrich
L-赖氨酸 单盐酸盐, reagent grade, ≥98% (HPLC)
Supelco
油酸, analytical standard
Sigma-Aldrich
二苄醚, 98%
Sigma-Aldrich
四氯化钛(IV) 溶液, 1.0 M in methylene chloride
Sigma-Aldrich
油酸, natural, FCC
Sigma-Aldrich
L-赖氨酸 单盐酸盐, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, 98.5-101.0%
Sigma-Aldrich
钙黄绿素-AM, BioReagent, suitable for fluorescence, ≥95.0% (HPLC)
Sigma-Aldrich
油酸, meets analytical specification of Ph, Eur., 65.0-88.0% (GC)
Supelco
L-赖氨酸 单盐酸盐, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
二苄醚, purum, ≥98.0% (GC)
Supelco
罗丹明B, analytical standard
Sigma-Aldrich
钙黄绿素AM 溶液, 4 mM in DMSO, ≥90% (HPLC), solution
Sigma-Aldrich
钙黄绿素-AM, Small Package (20 X 50 μg ), ≥95.0% (HPLC)
Sigma-Aldrich
L-赖氨酸 单盐酸盐, BioUltra, ≥99.5% (AT)
赖氨酸 盐酸盐, European Pharmacopoeia (EP) Reference Standard
Supelco
罗丹明 B 溶液, 0.2% in isopropanol, for TLC derivatization
Supelco
L-赖氨酸盐酸盐 溶液, 100 mM amino acid in 0.1 M HCl, analytical standard
Supelco
L-赖氨酸 单盐酸盐, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
二苄醚, ≥98%, FCC, FG
Supelco
油酸, Selectophore, ≥99%
油酸, European Pharmacopoeia (EP) Reference Standard
二苄醚, European Pharmacopoeia (EP) Reference Standard